Sunglasses with secret marijuana bowl allow you to smoke anywhere
These $100 sunglasses double as a smoke pipe
Biden Defeated Trump to Win the Election. Here’s How Much You Would Pay Under His Tax Plan.
Former Vice President Biden has a detailed proposal that involves raising taxes on people with taxable income of more than $400,000—essentially targeting the top 1%. President Trump wants to keep the tax cuts that went into effect in 2018, which largely benefited top earners.
Zoom Founder Drops $5 Billion as Vaccine Hits Covid Winners
(Bloomberg) — Eric Yuan is, in many ways, the poster child for the coronavirus economy.His Zoom Video Communications Inc. has hosted school lessons, family gatherings and business meetings for more than 300 million participants a day during the pandemic. The stock of the video conferencing site has soared more than 500% this year and Yuan, a Chinese-born immigrant to the U.S., was at one point worth $28.6 billion — the 40th wealthiest person on the planet.That remarkable surge took a hit Monday after Pfizer Inc. said the Covid-19 vaccine it’s developing with BioNTech SE prevented more than 90% of infections in a study, the most encouraging scientific advance so far in the battle against the virus. Airlines, oil giants and hotel operators surged, but stocks that benefited from lockdowns and work-from-home arrangements — such as Peloton Interactive Inc., Netflix Inc. and Sea Ltd., Southeast Asia’s largest internet company — all slumped. On Tuesday, the rout continued in Asia for glovemakers that saw demand surge this year. The key question now is whether those extraordinary gains can hold, or whether people will stop using the services of companies like Zoom after the pandemic ends and they return to the workplace.‘Normal Volatility’“I don’t think the trend around e-commerce, video collaboration or shift-to-cloud will change as a result of the vaccine,” said Bloomberg Intelligence analyst Mandeep Singh. “The valuations look rich for some of these names, but some of these are multi-year growth stories. This is just normal volatility as investors look to rotate into sectors that have been depressed due to the pandemic such as travel, casinos and hospitality.”Zoom shares fell 17% in New York on Monday, erasing $5.1 billion from Yuan’s net worth. He’s sold more than $275 million of Zoom stock in 2020 and is still worth $20 billion, according to the Bloomberg Billionaires Index. Peloton founder John Foley became a billionaire on the stunning rise in the home-fitness company’s shares. He’s down $300 million after the stock tumbled 20%. Reed Hastings, chief executive officer of movie and television streaming service Netflix, saw his wealth decline by $416 million. Forrest Li, the billionaire behind Singapore-based Sea, lost almost $1 billion as his company’s American depositary receipts fell 9.5% in the U.S. Monday. Glovemakers, which produced at least five billionaires as their shares surged during the pandemic, sank on Tuesday. Top Glove Corp., the world’s biggest rubber glove maker, lost as much as 11% in early trading in Malaysia. Riverstone Holdings Ltd. plunged 13%, while Hartalega Holdings Bhd., Kossan Rubber Industries Bhd. and Supermax Corp. all fell more than 8%, sinking the fortunes of their owners. FedEx Corp. Chairman Fred Smith’s net worth dropped by about $250 million as shares of the express shipping company fell 5.7%. His wealth had surged this year by more than 70% through Friday as remote working and booming e-commerce boosted demand for package-delivery services. Jay Chaudhry, CEO of cybersecurity firm Zscaler Inc. and Tim Steiner, the co-founder of U.K. online supermarket Ocado Group Plc, also slumped in the fallout of Pfizer’s vaccine study.‘Ortega, Rowling’Some firms and their billionaire owners are holding onto their gains. The fortunes of Zara founder Amancio Ortega and his daughter Sandra surged through their stakes in fast-fashion retailer Inditex SA as the vaccine study boosted hopes of consumers returning to brick-and-mortar shops. Hotelier Robert Rowling, as well as industrialist Georg Schaeffler and the Deichmann family who control one of Europe’s largest shoe retailers also saw their wealth increase Monday.Some companies are optimistic that even after the pandemic is brought under control, people will continue to use their services.“How can anybody be tired of Zoom?” CEO Kelly Steckelberg said in a June interview with Bloomberg TV. “Video communication has been integrated into all aspects of our lives.”(Updates to include Asian companies from third paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Cramer: Buy Airline Stocks On Rally Instead Of Cloud Stocks On Dips
Jim Cramer shared his thoughts on what the potential COVID-19 vaccine from Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) means for technology stocks that traded higher as stay at home plays.Stay-At-Home Stocks: Cramer said the S&P 500 and Dow are up the correct amount, but the Nasdaq futures are up too much. He said many of the companies in the Nasdaq don’t benefit from the vaccine.Cramer said the vaccine coming is not good news for cloud stocks and not good for the big run-up in stay-at-home stocks.Some of the companies have risen this year as stay-at-home plays: “How many Nasdaq stocks can rally on this?”Cramer said some stocks are rallying on Joe Biden being elected and the potential positives from improved relations with China and that’s okay.Related Link: Biden And Trump React To Pfizer’s Vaccine Update, Stock Market Rally: Great News! Buy Airlines: Cramer said the stocks that are rallying like airlines and theme parks are making the right moves. Cramer said he would be “much more comfortable buying an airline stock up 10% than a cloud stock down 5%.” Andrew Ross Sorkin asked Cramer if the stocks that are moving higher are worth buying since the timeline on approving a COVID-19 vaccine hasn’t changed. Cramer said if you wait to buy, you’ll miss the whole move” “Stocks trade in anticipation.” Cramer said there are “many, many companies that benefit.”Price Action: The SPDR S&P 500 Trust ETF (ARCA:SPY) is up 4% to $365.75 in pre-market trading. The Invesco QQQ ETF (NASDAQ: QQQ) is up 1% to $296.55.Airline stocks are rallying higher, with Southwest Airlines Co (NYSE: LUV) shares are up 15%, American Airlines Group (NASDAQ: AAL) shares are up 25% and JetBlue Airways Corporation (NASDAQ: JBLU) shares are up 18%.The U.S. Global JETS ETF (NYSE: JETS) is up 20% to $21.35 on Monday.See more from Benzinga * Click here for options trades from Benzinga * Biden And Trump React To Pfizer’s Vaccine Update, Stock Market Rally: ‘Great News!’ * Kids Pushing Parents To Buy Electric Vehicles: Study(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Biden And Trump React To Pfizer’s Vaccine Update, Stock Market Rally: ‘Great News!’
Pfizer Inc (NYSE: PFE) and partner BioTech SE (NASDAQ: BNTX) reported interim analysis of a Phase 3 study on coronavirus candidate BNT 162b2.The trial showed a 90% efficacy rate at the seven-day mark after a second dose of the vaccine was applied.The trial began July 27 and the companies have enrolled 35,358 healthy volunteers in the trial.The overall market is surging on the news, with the SPDR S&P 500 Trust ETF (NYSE: SPY) up 5% to $366.29 in pre-market trading. Dow futures are set to soar 5%, or about 1,300 points.Related Link: Pfizer-BioNTech’s COVID-19 Vaccine Is 90% Effective, EUA Filing Likely By Late NovemberJoe Biden’s Reaction: In a statement, president-elect Joe Biden said he was informed last night of the study results. He reminds Americans that it could be months before approval and people have access to the vaccine.”I congratulate the brilliant women and men who helped produce this breakthrough and to give us such cause for hope,” he said.While staying positive, Biden also took the time to remind Americans to wear masks, practice social distancing and wash their hands.”A mask remains a more potent weapon against the virus than the vaccine.”Biden also said America is losing over 1,000 people a day to Covid-19 and cases are rising.”Today’s news is great news, but it doesn’t change that fact,” Biden said on wearing masks.Donald Trump’s Reaction: President Donald Trump took to Twitter to say the following:> STOCK MARKET UP BIG, VACCINE COMING SOON. REPORT 90% EFFECTIVE. SUCH GREAT NEWS!> > — Donald J. Trump (@realDonaldTrump) November 9, 2020Trump’s first comment on the vaccine news was the impact it;s having on the stock market.The tweet from Trump broke a string of tweets from last night that shared Fox News videos that were labeled by Twitter as “this claim about election fraud is disputed.”What’s Next: Pfizer will continue safety data on the trial. The company plans on submitting the vaccine for emergency use authorization.Pfizer said it can produce up to 50 million vaccines in 2020 and up to 1.3 billion doses in 2021.Shares of Pfizer are up 14% to $41.65 in pre-market trading. Shares of BioNTech are up 25% to $114.88 in pre-market trading.See more from Benzinga * Click here for options trades from Benzinga * S&P 500 Rises 1% Each Of The Last 4 Days, Something Done Only 3 Times Since WWII * How The Betting Odds For Trump, Biden Fluctuated On Election Night(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Beyond Meat earnings miss big on declining food service and consumer demand
Beyond Meat’s partnership with McDonald’s to develop the McPlant burger wasn’t enough to keep shares from collapsing after the company posted third-quarter earnings that fell far below analysts’ expectations. “Our financial results reflect a quarter where for the first time since the pandemic began, we experienced the full brunt and unpredictability of COVID-19 on our net revenues and accordingly, throughout our P&L,” Beyond Meat’s president and chief executive, Ethan Brown, said in a statement.
7 Best Value Stocks to Buy in 2020
The 2010s were dominated by growth stocks, and when 2020 rolled around, many investors felt that it was time for value stocks to take the lead. Theoretically, a bear market would be the perfect time for value stocks to outperform growth, but year to date, many value names have continued to underperform their growth-minded peers; cheaply priced energy companies, in particular, kept getting cheaper as oil prices fell alongside plummeting demand amid the pandemic. The only financial stock on this list, the $5.2 billion OneMain Holdings is a consumer credit and insurance business that happens to be priced fairly conservatively.
Stock Market Today With Jim Cramer: Sell Pfizer
Jim Cramer discusses the latest stock market news including about McDonald’s, Pfizer and the stock market rally on Monday.
Berkshire Hathaway Appears to Have Sold About $4 Billion of Apple Stock in Third Quarter, According to Filings
Berkshire Hathaway, overseen by CEO Warren Buffett, also was a seller of financial stocks and a buyer of industrial stocks in the third quarter, according to filings.
Buy Fisker Stock Because the Price Could Double, Analyst Says
Cowen analyst Jeffrey Osborne issued a Buy Rating on Monday. He sees shares hitting $22, up from Friday’s close of $10.86. The shares were up more than 30% in midday trading.
Dow Jones Futures: Apple, Microsoft Lead Five Stocks For Coronavirus Vaccine Or Pandemic Market
The Pfizer vaccine news roiled coronavirus plays Monday. Look for leaders that thrive amid a vaccine stock market or coronavirus pandemic.
Pfizer’s Covid-19 Vaccine Just Might Work. What That Means for Moderna and Other Vaccine Stocks.
The pharmaceutical giant’s good news could be good news for other vaccine makers who are far along in the testing process.
Electric Car Sales More Than Double In World’s Biggest EV Market, But Tesla Lags
Tesla trailed local Chinese players in a hot Chinese market for electric cars. But Tesla stock rose early Monday as it works on abuy point.
These 3 Penny Stocks Could Rally Over 100%, Says Roth Capital
Does high risk mean high reward? Not necessarily, so say the pros on Wall Street. Specifically citing penny stocks, or stocks that trade for less than $5 per share, analysts advise caution as these names might still be in the early innings, or it could be that they face an uphill battle that is just too steep.Luring investors with their bargain price tags, these stocks might be up against overpowering headwinds or have weak fundamentals.However, analysts argue there are early-stage companies that reflect promising opportunities, with the low share prices meaning you get significantly more bang for your buck. What’s more, even what seems like minor share price appreciation can result in massive percentage gains.The bottom line? Not all risk is created equal. To this end, the pros recommend doing some due diligence before making an investment decision.With this in mind, we turned to investment firm Roth Capital for some inspiration. The firm’s analysts have pinpointed three compelling penny stocks, noting that each could climb over 100% higher in the year ahead. Using TipRanks’ database, we found out what makes all three such exciting plays even with the risk involved. CohBar (CWBR)Focused on developing mitochondria-based therapeutics (MBTs), CohBar wants to find new treatments for diseases associated with aging and metabolic dysfunction. Based on the strength of its technology and its $0.96 share price, Roth Capital thinks that now is the time to pull the trigger.Writing for the firm, analyst Elemer Piros points out that CWBR was able to turn over 100 mitochondrial peptides into 1,000 mitochondrial-based therapeutics (MBT). Company scientists and researchers from around the world have found that mitochondrial peptides regulate multiple physiological systems, including risk factors which lead to cardiovascular and neurodegenerative diseases, obesity, diabetes, fatty liver disease fibrotic and inflammatory conditions and cancer.It should be noted that peptides are either continually or intermittently released to modulate biological functions, but it’s difficult to deliver them as therapies. Additionally, they also tend to have shorter half-lives. “CohBar developed methods to modify peptides and plan to use modified analogues for clinical development,” Piros commented.Up first for CWBR is CB4211, its optimized analog of the MOTS-c mitochondrial-derived peptide. The company’s first clinical candidate is wrapping up a Phase 1b trial in patients with fatty liver disease. According to management, there are 10 patients who will be randomized for treatment with CB4211 and 10 for placebo, with the results expected in Q1 2021.Nonalcoholic Fatty Liver Disease (NAFLD) is a condition defined by excessive fat accumulation in the form of triglycerides (steatosis) in the liver in individuals who consume little or no alcohol. What’s more, the company will also target non-alcoholic steatohepatitis (NASH), which is the most severe form of NAFLD.Piros acknowledges that competition in the space is fierce, but says “no winners can be identified, yet.” Expounding on this, the analyst stated, “CB4211 offers a yet unexplored mechanism of action, which is foundational, based on the natural control of homeostasis, which is lost due to environmental or genetic insults. The compound was derived from naturally occurring mitochondrial peptides, with the purpose of restoring, rebalancing homeostasis with the goal of reversing disease processes.”Based on the above, Piros sees an attractive risk/reward in CWBR shares. “[We] value CohBar based on a comparable universe of early- to mid-stage companies with platforms that could yield multiple drug candidates. The average enterprise value of this group of companies is $268MM vs. CohBar at $38MM. We project that CohBar shares could trade in line with the average,” the analyst concluded.To this end, Piros rates CWBR a Buy along with an $8 price target. Should his thesis play out, a potential twelve-month gain of 741% could be in the cards. (To watch Piros’ track record, click here)Overall, CWBR has a small, but vocal camp of bullish analysts with positive expectations for its stock. Out of the 2 analysts polled by TipRanks, both rate the stock a Buy. With a return potential of 557%, the stock’s consensus price target stands at $6.25. (See CWBR stock analysis on TipRanks)Eyenovia (EYEN)By utilizing its patent piezo-print delivery technology, Eyenovia is developing a pipeline of micro-dose therapeutics. With shares changing hands for $3.41 apiece, Roth Capital sees an attractive entry point for investors.In October, Eyenovia announced that an affiliate of Bausch Health Companies had acquired an exclusive license in the U.S. and Canada for the investigational microdose formulation of atropine ophthalmic solution (MicroPine), designed for the reduction of myopia progression in children aged 3-12. MicroPine, which is delivered via EYEN’s proprietary Optejet dispenser, is progressing through Phase 3, with the launch potentially coming in 2025.As per the terms of the agreement, Bausch will assume the oversight and expenses related to the ongoing Phase 3 CHAPERONE trial. In turn, Eyenovia will receive a $10 million upfront payment and up to $35 million in approval and launch-based milestones, along with royalties ranging from mid-single digit to mid-teen percentages of gross profit on sales in the U.S. and Canada.Roth Capital’s Jonathan Aschoff tells clients that “the deal validates the technology and the market.” He adds that this agreement and the recent Asian MicroPine deal with Arctic Vision, “combined with the roughly $25 million in R&D savings for EYEN that these two deals provide, should improve EYEN’s cash flow by about $100 million over the next several years.” To this end, he argues that the company’s cash position should support its operations into 1H22.On top of this, assuming there aren’t any COVID-related delays, Aschoff believes EYEN should be able to initiate both Phase 3 VISION trials for MicroLine, its piezo-formulation of pilocarpine designed to replace reading glasses for three to four hours while addressing instillation and tolerability issues associated with traditional eye drops, by YE20. This means that trials will be able to enroll in a few weeks, and the results could be published in 2021.If that wasn’t enough, the company is planning to file the MicroStat (its mydriasis candidate) NDA by YE20, with the U.S. launch potentially coming in late 2021. “MicroStat commercialization should be aided by the current pandemic, given that physicians are more reluctant that ever before to reuse the same eyedropper for multiple patients, and with reuse generally encompassing about 20-30 patients, the eyedropper just became about 20-30 times more expensive for the physician,” Aschoff explained.It should come as no surprise, then, that Aschoff left a Buy rating and $11 price target on the stock. Given this target, shares could soar 223% in the next year. (To watch Aschoff’s track record, click here)Looking at the consensus breakdown, 2 Buys and no Holds or Sells have been issued in the last three months. Therefore, EYEN gets a Moderate Buy consensus rating. Based on the $8.50 average price target, shares could gain 150% in the coming months. (See EYEN stock analysis on TipRanks)Boqii Holding (BQ)Last but not least we have Boqii Holding, which operates the largest online platform for pet products in China, with its primary focus on online retail through third-party Chinese online platforms and its own e-commerce site (Boqii Mall). Currently going for $4.45 apiece, Roth Capital believes its share price presents a chance to get in on the action.Representing the firm, analyst Darren Aftahi told clients, “BQ represents an early-stage opportunity for investors to gain exposure to China’s leading ecosystem for all things pets, which uniquely blends ‘community’ and ‘commerce’ into an omni-channel, verticalized online and offline platform.”Part of what makes BQ so compelling is that although it primarily operates as an e-commerce company, it boasts an omni-channel, verticalized platform for pet products, in Aftahi’s opinion. Additionally, the company has integrated into offline channels like pet stores and hospitals. The analyst argues this not only expands the consumer access points, but the online community also keeps users engaged with various forms of content and marketing, “enhancing overall platform value to end customers.”According to Frost & Sullivan, China’s pet population growth is projected to be among the fastest over the next several years, with it expected to match U.S. ownership (400 million pets) by 2024 from approximately one-third that rate currently. “We believe BQ can see accelerated growth when we layer on the continued adoption of e-commerce spend, with online pet retail spend expected to reach 52% of total pet retail by 2024,” Aftahi commented.It should be noted that over 60% of sales come from BQ stores on third-party sites like Tmall, JD.com and Pinduoduo, which Aftahi thinks “broadens BQ’s brand reach.”Offering further explanation, the analyst stated, “These sites are often the initial touchpoint, and users can then be funneled into BQ’s online community for re-targeting, giving BQ an upper hand in customer ownership. In our view, BQ is set to capture growth from the shift to e-commerce, diversified across access points, but under the BQ brand regardless.”Everything that BQ has going for it prompted Aftahi to keep his Buy rating as is. Along with the call, he leaves the price target at $10, suggesting 123% upside potential. (To watch Aftahi’s track record, click here)When it comes to other analyst activity, it has been quiet. As Aftahi is the only analyst that has published a review recently. (See BQ stock analysis on TipRanks)To find good ideas for penny stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
Does Pfizer Vaccine News Make Carnival Stock A Buy Right Now? Here’s What Earnings, Charts Show
Ah, “Carnival.” The name conjures smiles. And some cruise lines are about to resume trips. So is this a good time or bad time to invest in Carnival?
130% Increase In Fuel Cell Units Deployed Drives Plug Power’s Best Quarter Yet
Shares of Plug Power rallied Monday after the hydrogen fuel cell company reported third-quarter results. Plug Power Q3 Earnings: New records were set by Plug Power Inc (NASDAQ: PLUG) in its third quarter.The company reported record gross billings of $125.6 million. This total was up 100% year-over-year and up 73% sequentially.This figure represents the highest gross billings in the company’s 22-year history, Plug Power said.The company raised its full-year billings guidance to a range of $325 million to $330 million. The prior guidance was for $310 million.Plug Power’s New Deals: In the third quarter, Plug Power signed deals with Brookfield Energy, a Brookfield Renewable Partners (NYSE: BEP) company and Apex Clean Energy.The signed deals are to source renewable electricity and build liquid green hydrogen plants.In the third quarter, Plug Power also signed a deal with Linde (NYSE: LIN) to deploy pilot Class 6 and Class vehicles on the road in 2021.Related Link: Linde Will “Be Our Savior” In Hydrogen Powered Solution, Cramer SaysView more earnings on PLUGPlug Power’s Strong Demand: Plug Power deployed 4,100 fuel cell systems and 13 hydrogen fueling stations in the third quarter. This marked a 130% year-over-year increase in fuel cell units deployed.At the height of the pandemic, Plug Power’s products were operating at 99% efficiency, the company said.The company moved 30% of retail food and groceries in the United States, according to the third-quarter shareholder letter. The corporate partners mentioned in the quarterlyreport were Wal-Mart Inc (NYSE: WMT), Amazon.com (NASDAQ: AMZN), Kroger Co (NYSE: KR), Supervalu and Wegmans.What’s Next For Plug Power: Plug Power highlighted its 2024 vision in the earnings release.The company said it remains on track to hit $1.2 billion in annual sales, $200 million in operating income and $250 million in adjusted EBITDA by 2024.The company is building five green hydrogen plants in the United States, with the first two set to be completed by 2022.The world’s first PEM technology Gigafactory is set to be operational by mid-2021. The factory will have 1.5 gigawatt-hours of capacity with room for expansion, Plug Power said. PLUG Price Action: Shares of Plug Power gained 7.69% Monday, closing at $20.31. Shares hit a new 52-week high of $21.89 earlier Monday and are up nearly 500% year-to-date.See more from Benzinga * Click here for options trades from Benzinga * Linde Will ‘Be Our Savior’ In Hydrogen-Powered Solution, Cramer Says(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Nikola Rises Late On ‘Continuing’ GM Talks; Workhorse, Kandi Kick Off Heavy Slate Of EV Earnings
Niikola stock rose late as the EV truck startup said GM talks continue. Workhorse kicked off earnings from electric car stocks, but gave weak production guidance.
Nio will be a ‘winner’ in EV market, analyst says
Nio Inc. got a bullish endorsement from J.P. Morgan analyst Rebecca Wen, as she raised her stock price target on the belief the Shanghai-based company will be a “winner” in the electric vehicle market.
Lowe’s Is Said to Be in Talks to Acquire HD Supply
(Bloomberg) — Home improvement retailer Lowe’s Cos. is in preliminary talks to buy building products distributor HD Supply Holdings Inc., according to people familiar with the matter.The companies have been discussing a deal with advisers, though no final decision has been made, said the people, who asked to not be identified because the matter isn’t public. While Lowe’s approached HD Supply recently, it doesn’t currently plan to proceed with a deal, one of the people said.It’s unclear whether HD Supply is talking to other suitors.Representatives for HD Supply and Lowe’s didn’t immediately respond to requests for comment.HD Supply gained more than 16% in after hours trading on Monday.The stock rose 0.6% to close at $43.75 in New York, giving the company a market value of about $7.1 billion. Lowe’s fell 8.9% to close at $153.45, giving it a market value of about $116 billion.HD Supply used to be owned by Lowe’s rival Home Depot Inc., which sold the company to private equity firms in 2007. They took it public about six years later.One of the largest industrial distributors in North America, HD Supply provides everything from bleach, to doors and ceramic tile to about 500,000 customers from 270 branches and 44 distribution centers, according to its annual report.Lowe’s, like the larger Home Depot, has been thriving during the pandemic.Sales have skyrocketed this year with socially-distancing Americans splurging on their properties at home-improvement chains that stayed open because they were deemed essential.With more customers than ever before, Lowe’s is trying to ride the momentum into winter — generally its slowest quarter before busy spring cleanups — by stocking up on more holiday gifts than usual, like trampolines and Ninja air fryers.(Updates with additional details in second paragraph; updates shares in fifth paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Artificial Intelligence Stocks To Buy And Watch Amid Rising AI Competition
When looking for the best artificial intelligence stocks to buy, identify companies using AI technology to improve products or gain a strategic edge, such as Microsoft, Netflix and Nvidia.
CEO: ‘It’s almost impossible’ to find a pension plan that provides retirement income
As pension plans fade, today’s investors may want to look to annuities to bridge the retirement gap, one expert said.
These $100 sunglasses double as a smoke pipe
We are Frame & Optic Inc. and we carry the newest styles and the latest trends in the eyewear industry, all of which are suited for any retail business. We stand by our products 100%, and we make sure that you are happy.
Contact us today
New Styles Weekly
Check back with our website; we always update our product list. We’re on top of the fashion trends and we want you in the know.
Fast Worldwide Shipping
We offer comprehensive global shipping options for businesses across the globe.
Private Label Specialist
Looking to build your own brand or want to create a promotional product for your business? Contact us today at (714) 794-5326 for more details.
- By Style
- Novelty Glasses
- Marijuana Leaf Ganja Bud Pot Weed Fun Novelty Party Sunglasses
- Delivery Info
Write Your Own Review
Only registered users can write reviews. Please, log in or register
Other people marked this product with these tags:
Use spaces to separate tags. Use single quotes (‘) for phrases.
Shipping Update regarding COVID Response
We are experiencing slight shipping delays due the to Global Pandemic. We are working with our Carriers such as UPS/FedEx, Fulfilment Partners & Local Warehouse thru these difficult times and have taken precautionary measures to maintain Public Health & Safetly Standards in addtion to State & Local Mandates. Please allow a 1 to 2 extra days and be mindful when selecting a carrier, as not all shiments will be delivered on their estimated delivery times. We are not responsible for refunding shipping if delivery times are not met.
Please allow 1-2 Business days to process your order. You may select your preferred method of delivery during checkout. We use the most effective carrier catered to your business needs. We currently ship with FedEx, UPS, USPS & DHL.
Actual shipping charges will be calculated base on the size and the weight of the purchased merchandise then added to the grand total of your order. Please be noted we use UPS shipping services, customers can benefit from the best discounted rate with UPS due to our large shipping volume.
The turnaround time for orders are usually within 72 hours after payment is received and all related information is completed. All orders are shipped on the same day or next business day. We always try our best to process your order as soon as possible. However during peak season 24-48 hours of processing is expected. Express orders must be placed before 9:00am Pacific time zone, to ship on the same day. If you have special requests or certain needs of delivery, please call or email us so we can arrange the best shipping method for you. All Packages are shipped out UPS ground unless otherwise noted. If you wish to calculate UPS shipping cost and time, click here for UPS website. Below is the transit ground map to show you how many days UPS will take to ship from our warehouse to yours.
This dozen includes: 12 Green